艾多沙班在亚洲房颤患者中的有效性与安全性
本研究利用韩国国民健康保险服务数据库,纳入2014年1月至2016年12月新使用艾多沙班或华法林的房颤患者(艾多沙班n=4200,华法林n=31565),经倾向评分匹配后比较(艾多沙班n=4061,华法林n=12183)。结果显示艾多沙班较华法林显著降低缺血性卒中、颅内出血、胃肠道出血住院、大出血住院及全因死亡风险,且各亚组结果一致。
要点
- 艾多沙班较华法林降低缺血性卒中风险(HR 0.693;95%CI 0.487-0.959)。
- 艾多沙班较华法林降低颅内出血风险(HR 0.407;95%CI 0.182-0.785)。
- 艾多沙班较华法林降低全因死亡风险(HR 0.716;95%CI 0.549-0.918)。
核心结论
- 在真实世界亚洲房颤人群中,艾多沙班较华法林可能降低缺血性卒中、大出血及全因死亡风险,且在高危亚组中一致。
研究设计与样本
- 基于韩国国民健康保险服务数据库的回顾性队列研究,纳入2014年1月至2016年12月新使用艾多沙班(n=4200)或华法林(n=31565)的房颤患者,采用倾向评分匹配(1:3)后比较(艾多沙班n=4061,华法林n=12183)。
主要发现
- 匹配队列中位年龄72岁,中位CHA2DS2-VASc评分3分,基线特征均衡。
- 艾多沙班组缺血性卒中风险显著低于华法林组(HR 0.693;95%CI 0.487-0.959)。
- 艾多沙班组颅内出血风险显著低于华法林组(HR 0.407;95%CI 0.182-0.785)。
- 艾多沙班组胃肠道出血住院风险显著低于华法林组(HR 0.597;95%CI 0.363-0.930)。
- 艾多沙班组大出血住院风险显著低于华法林组(HR 0.532;95%CI 0.352-0.773)。
关键数值与推荐
- 所有亚组(年龄、性别、CHA2DS2-VASc评分、肾功能、艾多沙班剂量)均显示艾多沙班临床结局优于华法林。
临床怎么用
- 对于亚洲非瓣膜性房颤患者,艾多沙班可作为华法林的替代选择,尤其在高危亚组中可能获益一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unclear whether edoxaban shows better risk reduction of ischemic stroke, bleeding, and all-cause mortality than warfarin in Asian patients with nonvalvular atrial fibrillation (AF). OBJECTIVES: This study compared the effectiveness and safety of edoxaban with those of warfarin in a Korean population with AF. METHODS: Using the Korean National Health Insurance Service database, we included new users of edoxaban and warfarin in patients with AF from January 2014 to December 2016 (n = 4,200 on edoxaban, and n = 31,565 on warfarin) and analyzed the risk of ischemic stroke, intracranial hemorrhage (ICH), hospitalization for gastrointestinal (GI) bleeding, hospitalization for major bleeding, and all-cause death. The propensity score matching method was used to balance covariates across edoxaban and warfarin users. RESULTS: We compared a 1:3 propensity score-matched cohort of patients with AF who were new users of edoxaban and warfarin (n = 4,061 and n = 12,183, respectively). Baseline characteristics were balanced between the 2 groups (median age 72 years; median CHA2DS2-VASc [congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category (female)] score 3). Edoxaban users had a significantly lower risk of ischemic stroke (hazard ratio [HR]: 0.693; 95% confidence interval [CI]: 0.487 to 0.959), ICH (HR: 0.407; 95% CI: 0.182 to 0.785), hospitalization for GI bleeding (HR: 0.597; 95% CI: 0.363 to 0.930), hospitalization for major bleeding (HR: 0.532; 95% CI: 0.352 to 0.773), and all-cause death (HR: 0.716; 95% CI: 0.549 to 0.918) than warfarin users. All subgroups (age, sex, CHA2DS2-VASc score, renal function, edoxaban dose) showed better clinical outcomes with edoxaban than with warfarin. CONCLUSIONS: In this real-world Asian population with AF, edoxaban might be associated with reduced risk of ischemic stroke, major bleeding, and all-cause death compared with warfarin. These benefits were consistent across various high-risk subgroups.
引用
- Lee SR, Choi EK, Han KD, et al. Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety. J Am Coll Cardiol. 2018. PMID: 30115222. doi:10.1016/j.jacc.2018.05.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。